LUPRON DEPOT 30 MG
LEUPROLIDE ACETATE : 30 MG · DIN 02239833 · ABBVIE CORPORATION
Health Canada status: MARKETED
What is LUPRON DEPOT?
LUPRON DEPOT 30 MG contains LEUPROLIDE ACETATE : 30 MG. It is listed in the Health Canada Drug Product Database under DIN 02239833, held by ABBVIE CORPORATION, supplied as POWDER FOR SUSPENSION, SUSTAINED-RELEASE for INTRAMUSCULAR administration. Health Canada currently lists it as marketed, status dated 17-Dec-2013. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is LUPRON DEPOT used for?
Treatment of children with central precocious puberty (CPP); advanced prostate cancer; endometriosis (pain relief/lesion reduction); preoperative improvement of anemia due to uterine fibroids.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
What else is LUPRON DEPOT called?
The same molecule, LEUPRORELIN, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Procren Depot | Latin | Sweden |
| Enanton® Depot Dual | Latin | Sweden |
| Lucrin | Latin | South Africa |
| Procrin Depot | Latin | Sweden |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Product details and regulatory record
| DIN | 02239833 |
|---|---|
| Brand name | LUPRON DEPOT |
| Generic / active ingredient | LEUPROLIDE ACETATE : 30 MG |
| Manufacturer | ABBVIE CORPORATION |
| Strength | 30 MG |
| Dosage form | POWDER FOR SUSPENSION, SUSTAINED-RELEASE |
| Route of administration | INTRAMUSCULAR |
| Schedule | Prescription |
| ATC code | L02AE02 LEUPRORELIN |
| AHFS class | 68:18.08 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 17-Dec-2013 |
| Original market date | 1999-09-13 00:00:00 |
How is this product identified?
Purchase orders, customs paperwork and tender documents each ask for a different identifier, and a DIN written without its leading zeros is the single most common reason an order line fails to match. Every form Nexara accepts for this product is listed here.
| DIN (8-digit, as used in Nexara ordering) | 02239833 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2239833 |
| Brand name | LUPRON DEPOT |
| Active ingredient / INN | LEUPROLIDE ACETATE : 30 MG |
| ATC code | L02AE02 |
| ATC anatomical main group | L — Antineoplastic and immunomodulating agents |
| ATC therapeutic subgroup | L02 |
| AHFS class | 68:18.08 |
| Health Canada schedule | Prescription |
| Biosimilar biologic | No |
| Market authorization holder | ABBVIE CORPORATION |
How is it administered?
Intramuscular injection by healthcare professional. Dosing varies by indication: monthly (3.75/7.5mg), 3-month (11.25/22.5mg), 4-month (30mg), or 6-month (45mg) intervals. Reconstitute before use.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store at 15-30°C. Do not freeze. (Note: General depot storage standard, though specific text was cut off, 4.3 mentions stability for 24h post-reconstitution).
How is it supplied?
Single-dose kits containing one pre-filled dual-chamber USP Type I glass syringe with 23-gauge needle.
Which pack is which?
| Strength on the label | 30 MG |
|---|---|
| Dosage form | POWDER FOR SUSPENSION, SUSTAINED-RELEASE |
| Route | INTRAMUSCULAR |
| Packaging as described in the monograph | Single-dose kits containing one pre-filled dual-chamber USP Type I glass syringe with 23-gauge needle. |
| Storage | Store at 15-30°C. Do not freeze. (Note: General depot storage standard, though specific text was cut off, 4.3 mentions stability for 24h post-reconstitution). |
One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced. Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Contraindications
Hypersensitivity to drug/components/GnRH analogs; pregnancy or potential pregnancy; breast-feeding; undiagnosed abnormal vaginal bleeding (for fibroids/endometriosis).
Warnings and precautions
Prostate cancer: Clinical testosterone flare, osteoporosis. General: Hypersensitivity/anaphylaxis, delayed hypersensitivity, skin reactions. Monitor bone age in pediatrics.
What can be used instead?
Other Canadian products sharing ATC code L02AE02 LEUPRORELIN. 11 of 16 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ELIGARD | 22.5 MG | POWDER FOR SUSPENSION, SUSTAINED-RELEASE | TOLMAR INTERNATIONAL LTD. | MARKETED | DIN 02248240 |
| ELIGARD | 30 MG | POWDER FOR SUSPENSION, SUSTAINED-RELEASE | TOLMAR INTERNATIONAL LTD. | MARKETED | DIN 02248999 |
| ELIGARD | 45 MG | POWDER FOR SUSPENSION, SUSTAINED-RELEASE | TOLMAR INTERNATIONAL LTD. | MARKETED | DIN 02268892 |
| ELIGARD | 7.5 MG | POWDER FOR SUSPENSION, SUSTAINED-RELEASE | TOLMAR INTERNATIONAL LTD. | MARKETED | DIN 02248239 |
| LUPRON DEPOT | 11.25 MG | POWDER FOR SUSPENSION, SUSTAINED-RELEASE | ABBVIE CORPORATION | MARKETED | DIN 02239834 |
| LUPRON DEPOT | 22.5 MG | POWDER FOR SUSPENSION, SUSTAINED-RELEASE | ABBVIE CORPORATION | MARKETED | DIN 02230248 |
| LUPRON DEPOT | 3.75 MG | POWDER FOR SUSPENSION, SUSTAINED-RELEASE | ABBVIE CORPORATION | MARKETED | DIN 00884502 |
| LUPRON DEPOT | 7.5 MG | POWDER FOR SUSPENSION, SUSTAINED-RELEASE | ABBVIE CORPORATION | MARKETED | DIN 00836273 |
| ZEULIDE DEPOT | 22.5 MG | POWDER FOR SUSPENSION, SUSTAINED-RELEASE ; KIT | VERITY PHARMACEUTICALS INC. | MARKETED | DIN 02462699 |
| ZEULIDE DEPOT | 3.75 MG | POWDER FOR SUSPENSION, SUSTAINED-RELEASE ; KIT | VERITY PHARMACEUTICALS INC. | MARKETED | DIN 02429977 |
Who else supplies LEUPRORELIN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. LEUPRORELIN appears in 76 registered pack listings across 11 markets, published on 9 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How much does LEUPRORELIN cost around the world?
LEUPRORELIN is listed on 7 national price registers Nexara tracks, across 57 pack listings published on 6 different price bases. What each country publishes is set out below.
| Market | What that country publishes | Brands listed | Pack listings | As of |
|---|---|---|---|---|
| Hungary | producer price (ex-factory) | 10 | 13 | 03 Sep 2026 |
| Australia | ex-manufacturer | 9 | 11 | 08 Sep 2026 |
| Sweden | AIP (pharmacy purchase price) | 3 | 10 | 03 Sep 2026 |
| Greece | producer price (ex-factory) | 9 | 9 | 03 Sep 2026 |
| Romania | max producer price | 4 | 7 | 03 Sep 2026 |
| Saudi Arabia | public | 5 | 5 | 01 Sep 2026 |
| South Africa | single exit price | 2 | 2 | 01 Sep 2026 |
Why there are no figures here. These bases are not comparable. A Brazilian ex-factory ceiling, a Belgian pharmacy public price and a Japanese reimbursement rate answer three different questions, and none of them is what a product lands in Canada for. Putting them side by side would mislead in both directions, so Nexara publishes where a molecule is listed and on what basis, and quotes the delivered Canadian price per order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.